Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 3:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 10,825 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Interventions: Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Melphalan, Alemtuzumab 0.2 mg, Fludarabine phosphate 30 mg, MESNA; Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 50 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neonatal Abstinence Syndrome
Interventions: Low lactose or regular formula; Other
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 1 Minute to 7 Days
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Pain, Bunion, Abdominoplasty
Interventions: Wafermine™ 50 mg, Wafermine™ 75 mg, Placebos, Wafermine™ 25 mg; Drug
Lead sponsor: iX Biopharma Ltd.; Other
Eligibility: 18 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adrenocortical Carcinoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive, Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: cixutumumab, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Months to 30 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 93
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more

Conditions: Neurofibromatosis
Interventions: Gleevec; Drug
Lead sponsor: Indiana University; Other
Eligibility: 3 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
Interventions: AAV2-hRPE65v2,voretigene neparvovec-rzyl; Biological
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 12 Months and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Miami, Florida • Iowa City, Iowa + 6 more

Conditions: Von Willebrand Diseases
Interventions: Wilate; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 6 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Anemia, Sickle Cell, Pain
Interventions: Fentanyl Citrate, Normal Saline; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Cystic Fibrosis
Interventions: Initiation of CFTR Modulator; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 18 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin

Conditions: Congenital Heart Diseases, Children
Interventions: structured physical activity program; Other
Lead sponsor: Columbia University; Other
Eligibility: 30 Months to 6 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Premature Infant, Chronic Respiratory Disease, Neuromuscular Diseases, Healthy, Bronchopulmonary Dysplasia, Pulmonary Vein Stenoses
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Days to 40 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema
Interventions: SAR447537; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more

Conditions: Cystic Fibrosis
Interventions: Linezolid; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sanfilippo Syndrome Type C, Mucopolysaccharidosis (MPS) IIIC
Interventions: Not listed
Lead sponsor: Phoenix Nest; Industry
Eligibility: 1 Year to 25 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dermatitis, Atopic
Interventions: Efalizumab treatment; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Neoplastic Syndrome
Interventions: tazarotene; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 2
States / cities: Oakland, California • New York, New York

Conditions: Arginase I Deficiency, Hyperargininemia
Interventions: Pegzilarginase, Placebo; Drug
Lead sponsor: Immedica Pharma AB; Industry
Eligibility: 2 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 17
States / cities: Rogers, Arkansas • Orange, California • Stanford, California + 14 more

Conditions: Obstructive Sleep Apnea, Fetal Growth Restriction, Pregnancy Related
Interventions: S9 VPAP Adapt; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: St Louis, Missouri • Rochester, New York

Conditions: Cornelia de Lange Syndrome
Interventions: N-acetyl cysteine, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neoplastic Syndromes, Hereditary
Interventions: Web resources, Personalized outreach; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Denver, Colorado • Portland, Oregon

Conditions: Tourette Syndrome
Interventions: SCI-110, Placebo; Drug · Other
Lead sponsor: Neurothera Labs Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neurofibromatosis Type 1, Sarcoma
Interventions: filgrastim, doxorubicin hydrochloride, etoposide, ifosfamide, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Sarcoma Alliance for Research through Collaboration; Other
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 17
States / cities: Birmingham, Alabama • Santa Monica, California • Chicago, Illinois + 13 more

Conditions: Knee Osteoarthritis, Knee Arthritis, Knee Pain Chronic, Knee Deformity, Knee Pain Swelling, Muscle Weakness, Muscle Weakness Condition, Power
Interventions: Manual Physical Therapy; Procedure
Lead sponsor: Jennifer Moreno Clinic; Other
Eligibility: 45 Years to 74 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Lafora Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Role of Low Lactose Infant Formula In The Management of Neonatal Abstinence Syndrome

Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

Hyperpolarized Imaging for New Treatments

Physical Activity and Cognitive Development in Children

Genesis Electrical Impedance Tomography (EIT): A Preliminary Study

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Pharmacokinetics of Linezolid in Children With Cystic Fibrosis

Natural History to Assess Disease in Patients With MPS IIIC

Efalizumab for Eczema

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

Sleep Apnea and Fetal Growth Restriction

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

Applying Population Management Best Practices to Preventative Genomic Medicine Trial

SCI-110 in the Treatment of Tourette Syndrome

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Rate of Torque Development and Voluntary Quadriceps Activation in Patients With Knee Osteoarthritis: A Quantitative Analysis Before and After a Single Session of Manual Physical Therapy

Ketogenic Diet in Lafora Disease